Caladrius Biosciences

Caladrius Biosciences is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease.

Founded in 1980, the company was formerly known as Corniche Group Inc, Phase III Medical Inc, and NeoStem, Inc., it adopted its current name in 2015.

In 2022, Caladrius and Cend Therapeutics merged to form Lisata Therapeutics.

Cardiovascular disease
In 2012 it started a randomized, controlled, double-blind phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow-derived cell therapy enriched for CD34+ cells, for marked reduction in left ventricular function following acute myocardial infarction.

The published study results showed no evidence of benefit from pre-specified endpoints, though there appeared to be evidence suggesting possible dose-related benefit in post-hoc analysis from a subset of patients.